FCF Life Sciences Venture Capital Monitor – Europe 03/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 03/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of  March 2022 we identify the following current VC trends in Europe:
  • In 2022, overall Life Sciences funding has reached EUR 2,880m so farTop 5 Deals exceed EUR 70m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Bpifrance dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • The Biotech sector received 42% of the total investment volume, no change compared to the previous month
  • Oncology dominates as the top indication of the Biotechnology sector
To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link
Share on linkedin
Share